Senti Biosciences

Senti Biosciences Holdings, Inc. is a clinical-stage synthetic biology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform and Regulator Dial technology platform. The company's lead clinical asset, SENTI-202, was a logic-gated CAR-NK cell therapy for relapsed/refractory AML that received RMAT designation from FDA. On July 15, 2026 the company announced a strategic transaction spinning off its Gene-Circuit-enabled pipeline (including SENTI-202) into a newly formed private company controlled by Celadon Partners (Senti's largest investor) in exchange for a contingent value right worth up to $60M in milestone payments over seven years. Post-transaction, the retained company plans to focus on early-stage Regulator Dial programs including a controllable gene therapy for Rett Syndrome and armored tumor-infiltrating lymphocytes (TILs) for solid tumors.